CSL Broadmeadows

As time goes by, we experience more advancements in the world of biotechnology. This progression means we can live longer, healthier lives, thanks to the innovation and collaboration of biotechnology companies. Here, CSL Seqirus shares more about safeguarding public health following their win at the International Life Sciences Awards 2023.

Seasonal influenza is an acute respiratory infection caused by influenza viruses which circulate in all parts of the world.1 Each year, influenza causes 3 to 5 million cases of severe illness and about 290,000 to 650,000 respiratory deaths.1 This, along with Covid-19, RSV and pneumococcal infections, continue to present major threats to health systems globally.2

CSL Seqirus works to safeguard public health from infectious diseases and supports several government bodies on their vaccine pandemic preparedness needs. The company has a rich heritage in public health protection that dates back to the Spanish Influenza Pandemic of 1916, and they’ve worked with global health partners on the front line ever since.

Helping to support public health protection from respiratory infections requires preparation. As part of their pandemic preparedness activities, CSL Seqirus monitors surveillance data on viruses circulating in animal reservoirs to help support public health agencies should the need arise. As part of this work, CSL Seqirus regularly interacts with the World Health Organisation (WHO) to help build a library of candidate vaccine viruses.

Of course, none of the work of CSL Seqirus would be possible without the hard work, flexibility, and passion of its team members, who strive to deliver solutions on time, every time.

Today, CSL Seqirus operates manufacturing facilities in three different continents. In the UK, the CSL Seqirus site is located in Liverpool, with approximately 620 employees. The safety record at the Liverpool manufacturing site shows how impactful it is when people take pride in what they do and speak up to avoid accidents and look out for each other. Everyone at CSL Seqirus is driven by their promise to stand with partners in public health discovering, developing and delivering solutions to safeguard people and communities across the world.

Winning the GHP Legacy Award in Biotechnology 2023, CSL Seqirus is honoured to receive this recognition for its contribution to the field.


This is an article fully sponsored and written by CSL Seqirus.



Contact Details:

Contact:  Emmanuella Dekonor

Company: CSL Seqirus



Published September 2023